RHYTHM PHARMACEUTICALS INC (RYTM) Forecast, Price Target & Analyst Ratings

NASDAQ:RYTM • US76243J1051

Current stock price

85.7 USD
+0.49 (+0.58%)
At close:
85.7 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RHYTHM PHARMACEUTICALS INC (RYTM).

Forecast Snapshot

Consensus Price Target

Price Target
$140.01
+ 63.37% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 5, 2026
Period
Q1 / 2026
EPS Estimate
-$0.87
Revenue Estimate
56.434M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.45%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$140.01
Upside
+ 63.37%
From current price of $85.70 to mean target of $140.01, Based on 22 analyst forecasts
Low
$106.05
Median
$142.80
High
$165.90

Price Target Revisions

1 Month
-1.82%
3 Months
-0.72%

Price Target Summary

22 Wall Street analysts provided a forecast for the next 12 months for RYTM. The average price target is 140.01 USD. This implies a price increase of 63.37% is expected in the next year compared to the current price of 85.7.
The average price target has been revised downward by 0.72% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RYTM Current Analyst RatingRYTM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

RYTM Historical Analyst RatingsRYTM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
85.45%
RYTM was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about RYTM.
In the previous month the buy percentage consensus was at a similar level.
RYTM was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-23HC Wainwright & Co.Maintains Buy -> Buy
2026-03-20CitizensMaintains Market Outperform -> Market Outperform
2026-03-20B of A SecuritiesMaintains Buy -> Buy
2026-03-20CitigroupMaintains Buy -> Buy
2026-03-18HC Wainwright & Co.Maintains Buy -> Buy
2026-03-17CitizensMaintains Market Outperform -> Market Outperform
2026-03-17NeedhamMaintains Buy -> Buy
2026-03-17RBC CapitalMaintains Outperform -> Outperform
2026-03-17B of A SecuritiesMaintains Buy -> Buy
2026-03-17Morgan StanleyMaintains Overweight -> Overweight
2026-03-17CitigroupMaintains Buy -> Buy
2026-03-12Wells FargoMaintains Overweight -> Overweight
2026-03-02Canaccord GenuityMaintains Buy -> Buy
2026-03-02HC Wainwright & Co.Maintains Buy -> Buy
2026-02-27CitizensMaintains Market Outperform -> Market Outperform
2026-02-27GuggenheimMaintains Buy -> Buy
2026-02-27Wells FargoMaintains Overweight -> Overweight
2026-02-26NeedhamMaintains Buy -> Buy
2026-02-19RBC CapitalInitiate Outperform
2026-01-20Wells FargoMaintains Overweight -> Overweight
2026-01-20HC Wainwright & Co.Maintains Buy -> Buy
2026-01-09NeedhamMaintains Buy -> Buy
2025-12-22HC Wainwright & Co.Maintains Buy -> Buy
2025-12-17GuggenheimMaintains Buy -> Buy
2025-12-12CitizensMaintains Market Outperform -> Market Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 5, 2026
Period
Q1 / 2026
EPS Estimate
-$0.87
Revenue Estimate
56.434M
Revenue Q2Q
72.56%
EPS Q2Q
-7.66%
Number of Analysts
17

Next Earnings Revisions

Revenue (1 Month)
-2.07%
Revenue (3 Months)
-5.09%
EPS (1 Month)
-1.50%
EPS (3 Months)
-9.30%

Next Earnings Summary

RYTM is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.87 USD and the consensus revenue estimate is 56.43M USD.
The next earnings revenue estimate has been revised downward by 5.09% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RYTM revenue by date.RYTM revenue by date.
77.428M
227.53%		130.126M
68.06%		189.757M
45.83%		294.77M
55.34%		548.44M
86.06%		888.9M
62.08%		1.483B
66.84%		2.096B
41.34%		2.42B
15.46%		2.835B
17.15%		3.345B
17.99%
EBITDA
YoY % growth
RYTM ebitda by date.RYTM ebitda by date.
-182.599M
-2.88%		-263.94M
-44.55%		-190.678M
27.76%		-204.503M
-7.25%		-41.912M
79.51%		202.93M
584.18%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
RYTM ebit by date.RYTM ebit by date.
-184.357M
-2.90%		-265.503M
-44.02%		-192.016M
27.68%		-203.21M
-5.83%		-23.787M
88.29%		334.09M
1,504.48%		791.02M
136.77%		1.335B
68.77%		1.605B
20.22%		1.945B
21.18%		2.382B
22.47%
Operating Margin
RYTM operating margin by date.RYTM operating margin by date.
-238.10%-204.04%-101.19%-68.94%-4.34%37.58%53.34%63.69%66.32%68.61%71.21%
EPS
YoY % growth
RYTM eps by date.RYTM eps by date.
-3.20
8.05%		-4.49
-40.31%		-3.11
30.73%		-3.20
-3.01%		-0.66
79.27%		3.60
642.33%		8.25
129.00%		12.65
53.38%		16.60
31.19%		19.01
14.55%		22.89
20.41%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.87
-7.66%		-0.82
-9.67%		-0.79
3.19%		-0.70
4.15%		-0.68
21.63%		-0.21
73.96%		0.25
131.48%		-0.67
4.52%
Revenue
Q2Q % growth		56.434M
72.56%		67.607M
39.39%		78.538M
53.10%		92.631M
61.79%		99.45M
76.22%		125.36M
85.42%		146.4M
86.41%		179.89M
94.20%
EBITDA
Q2Q % growth		-59.657M
-27.96%		-53.675M
-20.53%		-49.326M
4.38%		-39.913M
12.71%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-56.183M
-19.53%		-52.882M
-16.75%		-50.075M
4.90%		-47.202M
-0.30%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
46.71%
EPS Next 5 Year
43.42%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
66.81%
Revenue Next 5 Year
61.38%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
44.33%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

RHYTHM PHARMACEUTICALS INC / RYTM Forecast FAQ

Can you provide the average price target for RHYTHM PHARMACEUTICALS INC stock?

22 analysts have analysed RYTM and the average price target is 140.01 USD. This implies a price increase of 63.37% is expected in the next year compared to the current price of 85.7.

When does RHYTHM PHARMACEUTICALS INC (RYTM) report earnings?

RHYTHM PHARMACEUTICALS INC (RYTM) will report earnings on 2026-05-05.

Can you provide the consensus estimates for RHYTHM PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of RHYTHM PHARMACEUTICALS INC (RYTM) is -0.87 USD and the consensus revenue estimate is 56.43M USD.

What is the expected long term growth rate for RHYTHM PHARMACEUTICALS INC (RYTM)?

The expected long term growth rate for RHYTHM PHARMACEUTICALS INC (RYTM) is 66.81%.